Related Experiment Video
Updated: Aug 19, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass
Philippe-Primo Caimmi1, Lorenzo Pagani, Ezio Micalizzi
1Department of Cardiac Surgery, University of East Piedmont, School of Medicine, Novara, Italy. philippeprimo.caimmi@tin.it
Objective:
To evaluate the possible protective effects of fenoldopam on renal function in patients undergoing cardiopulmonary bypass.
Design:
Prospective, randomized trial.
Setting:
University teaching hospital.
Participants:
One hundred sixty consecutive patients with serum creatinine >1.5 mg/dL who underwent uncomplicated moderate hypothermic cardiopulmonary bypass for cardiac surgery.
Interventions:
A random group of 80 patients was managed conventionally (group A), whereas another random group of 80 patients received continuous intravenous administration of low-dose fenoldopam (0.1-0.3 microg/kg/min) during cardiopulmonary bypass and in the early postoperative period (group B).
Measurements And Main Results:
An improvement of postoperative renal parameters were observed only in group B: preoperative serum creatinine 1.82 +/- 0.2 versus 1.43 +/- 0.73 postoperatively (p < 0.001), preoperative creatinine clearance 51.34 +/- 22.26 versus 67.14 +/- 18.55 postoperatively (p < 0.001).
Conclusions:
In this study, fenoldopam was an effective agent in the prevention of renal dysfunction after cardiopulmonary bypass.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Cardiomyopathy VII: Pre and Post Operative Nursing Management

